Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

COVID-19 4Neoplasms 2Severe Acute Respiratory Syndrome 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Mastocytosis 1Lymphoma 1Leukemia, Myeloid, Acute 1Hypersensitivity 1Hematopoietic and Lymphatic System Neoplasm 1Hematologic Neoplasms 1

Interventions

Dexamethasone 3iniparib 2Poly(ADP-ribose) Polymerase Inhibitors 2Calcium Dobesilate 2dexamethasone acetate 1dexamethasone 21-phosphate 1asparaginase erwinia chrysanthemi recombinant 1amminedichloro(2-methylpyridine)platinum(II) 1ZD4054 1Vincristine 1Sodium Chloride 1Rituximab 1Paclitaxel 1Narrow Band Imaging 1Methotrexate 1Doxorubicin 1Dexrazoxane 1Cytarabine 1Carboplatin 1BNT162 Vaccine 1Asparaginase 12019-nCoV Vaccine mRNA-1273 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypersensitivity × BNT162 Vaccine × Clear all
NCT04761822 2025-08-12

SARS

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
746 enrolled 28 charts
Myeloid

COVID-19, Hypersensitivity, Mastocytosis, Severe Acute Respiratory Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡